Moreover, the weight loss response to anti-obesity medications (i.e. liraglutide, semaglutide and phentermine) seems poorer in obese breast cancer patients treated with aromatase inhibitors when compared to obese patients without breast tumours [119]. Here, CYP19A1 is linked to breast carcinoma.